US Bancorp DE Sells 4,330 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

US Bancorp DE trimmed its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 54.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,621 shares of the biopharmaceutical company’s stock after selling 4,330 shares during the quarter. US Bancorp DE’s holdings in Intra-Cellular Therapies were worth $302,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in ITCI. Assetmark Inc. increased its holdings in shares of Intra-Cellular Therapies by 9.1% in the third quarter. Assetmark Inc. now owns 2,477 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 207 shares during the last quarter. Atria Investments Inc grew its position in Intra-Cellular Therapies by 41.1% in the third quarter. Atria Investments Inc now owns 5,137 shares of the biopharmaceutical company’s stock worth $376,000 after acquiring an additional 1,497 shares in the last quarter. State of New Jersey Common Pension Fund D grew its position in Intra-Cellular Therapies by 0.6% in the third quarter. State of New Jersey Common Pension Fund D now owns 35,673 shares of the biopharmaceutical company’s stock worth $2,610,000 after acquiring an additional 223 shares in the last quarter. Versor Investments LP purchased a new position in Intra-Cellular Therapies in the third quarter worth about $257,000. Finally, Entropy Technologies LP purchased a new position in Intra-Cellular Therapies in the third quarter worth about $521,000. 92.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ITCI has been the subject of several recent research reports. Needham & Company LLC reiterated a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. StockNews.com initiated coverage on Intra-Cellular Therapies in a research report on Wednesday. They issued a “hold” rating for the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Leerink Partnrs lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Ten equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Intra-Cellular Therapies presently has a consensus rating of “Hold” and an average target price of $106.08.

Intra-Cellular Therapies Stock Up 0.1 %

Shares of NASDAQ:ITCI opened at $131.36 on Friday. Intra-Cellular Therapies, Inc. has a 52-week low of $63.30 and a 52-week high of $131.38. The stock has a market cap of $13.97 billion, a P/E ratio of -150.99 and a beta of 0.69. The business’s 50 day moving average is $123.00 and its 200 day moving average is $94.99.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. On average, sell-side analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.